本文已被：浏览 1293次 下载 65次
Received:July 17, 2024 Published Online:October 20, 2024
Received:July 17, 2024 Published Online:October 20, 2024
中文摘要: 目的 分析环状核糖核酸（circRNA）Hsa circ0016599在三阴性乳腺癌（TNBC）患者中的表达及其对新辅助化疗（NACT）疗效的影响及预测价值。
方法 回顾性选取2022年4月至2024年2月沧州市人民医院手术前接受NACT治疗的124例TNBC患者作为研究对象，对手术切除的癌组织、癌旁组织标本测定Hsa circ0016599表达情况，依据Hsa circ0016599相对表达水平中位值(2-ΔΔCt=15.12)分为低表达组(≤15.12， n=59)、高表达组(＞15.12， n=65)。比较124例TNBC患者癌组织、癌旁组织中Hsa circ0016599表达水平，比较低表达组、高表达组患者的NACT总有效率，筛选影响TNBC患者NACT疗效的危险因素，构建列线图模型。
结果 124例TNBC患者癌组织中Hsa circ0016599表达水平高于癌旁组织（19.76±4.31 vs 14.15±2.74, t=12.232，P＜0.01）。高表达组有区域淋巴结转移、脉管瘤栓、神经侵犯患者占比高于低表达组（P＜0.05），NACT总有效率低于低表达组（35.38% vs 62.71%, χ2=9.248, P＜0.01）；Hsa circ0016599高表达、存在区域淋巴结转移、有脉管瘤栓、有神经侵犯均为影响TNBC患者NACT疗效的危险因素（OR=1.264,1.239,1.257,1.247，P＜0.05）。Hsa circ0016599表达水平预测TNBC患者NACT疗效校准曲线显示模型预测价值较好。
结论 Hsa circ0016599在TNBC患者癌组织中呈高表达，且Hsa circ0016599高表达患者NACT总有效率相对较低，Hsa circ0016599对NACT疗效有一定预测价值。
中文关键词: 三阴性乳腺癌 环状核糖核酸 Hsa circ0016599 新辅助化疗 疗效
Abstract:ObjectiveTo analyze the expression of circular ribonucleic acid (circRNA) Hsa circ0016599 in patients with triple-negative breast cancer (TNBC) and its effect and predictive value for the efficacy of neoadjuvant chemotherapy (NACT).
Methods A total of 124 patients with TNBC who received NACT treatment before operation in Cangzhou Peoples Hospital from April 2022 to February 2024 were selected retrospectively as the research objects. The expression of Hsa circ0016599 was measured in the resected cancer tissues and adjacent tissues, and they were divided into low expression groups (≤15.12, n=59) and high expression group (＞15.12, n=65)according to the median relative expression value of Hsa circ0016599 (2-ΔΔCt=15.12). The expression levels of Hsa circ0016599 in cancer tissues and adjacent tissues of 124 TNBC patients and the total effective rates of NACT in low expression group and high expression group were compared. The risk factors affecting the efficacy of NACT in TNBC patients were screened to construct a nomogram model.
Results In 124 TNBC patients, the expression level of Hsa circ0016599 in cancer tissues was higher than that in adjacent tissues (19.76±4.31 vs 14.15±2.74, t=12.232, P＜0.01). Compared with the low expression group, the high expression group had a higher proportion of patients with regional lymph node metastasis, vascular tumor thrombus, and nerve invasion (P＜0.05), also had a lower total effective rate of NACT (35.38% vs 62.71%, χ2=9.248, P＜0.01）. High expression of Hsa circ0016599, presence of regional lymph node metastasis, vascular tumor thrombus, and nerve invasion were all risk factors affecting NACT efficacy in TNBC patients (OR=1.264, 1.239, 1.257, 1.247, P＜0.05). The calibration curve of Hsa circ0016599 expression level prediction model showed a good predictive value for NACT efficacy in TNBC patients.
Conclusion Hsa circ0016599 is highly expressed in the cancer tissues of TNBC patients, and the total NACT effective rate of patients with high expression of Hsa circ0016599 is relatively low, indicating that Hsa circ0016599 has a certain predictive value for NACT efficacy.
keywords: Triple-negative breast cancer Circular ribonucleic acid Hsa circ0016599 neoadjuvant chemotherapy Efficacy
文章编号： 中图分类号：R737.9 文献标志码：A
基金项目:河北省医学科学研究课题（20232094）
引用文本：